EQT Life Sciences Exits Tubulis Stake Through Gilead Sciences Deal Worth Up to $5 Billion
EQT Life Sciences has officially exited its minority stake in Tubulis, a clinical-stage biotechnology company based in Germany, through a significant agreement with Gilead Sciences that has the potential to reach a total of $5 billion. This move marks a noteworthy moment in the biotech landscape as Gilead solidifies its position within the oncology sector by acquiring Tubulis, which specializes in developing next-generation antibody-drug conjugates (ADCs).
The transaction includes a cash payment of approximately $3.15 billion at closing, along with contingent milestone payments that could total another $1.85 billion. This strategic acquisition is expected to close in the second quarter of 2026 and will help Gilead enhance its clinical stage pipeline, particularly in the field of oncology, where there remains a critical need for innovative therapies.
EQT’s involvement with Tubulis dates back to March 2024, when the LSP 7 fund participated in a significant Series B2 financing round. Since then, EQT Life Sciences has played a vital role in the company's growth, providing strategic guidance and active board involvement, which helped position Tubulis as a formidable contender in the rapidly evolving ADC market.
Tubulis is known for its lead candidate, TUB-040, an ADC targeting NaPi2b that is currently undergoing Phase 1b/2 trials for both platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). In addition to TUB-040, Gilead will also acquire TUB-030, another promising ADC that targets the 5T4 antigen, showing encouraging results in initial clinical trials across various solid tumor types. This acquisition also includes Tubulis' early-stage pipeline and its advanced ADC platform, signaling Gilead’s intent to innovate within this space significantly.
Dominik Schumacher, CEO and co-founder of Tubulis, expressed optimism about joining forces with Gilead, citing the potential to leverage their expertise and resources for accelerated development of their promising ADC pipeline. This relationship is expected to deepen as both companies have already collaborated, showcasing the complementary strengths that can now be harnessed to meet critical patient needs.
Comments from Christoph Broja, a partner at EQT Life Sciences, reflected confidence in Tubulis' potential, emphasizing the unique innovation and scientific expertise present within the company. The decision to support Tubulis from its early days is viewed as a testament to EQT’s strategy of investing in companies that demonstrate remarkable ambition and technological prowess.
Post-acquisition, Tubulis will operate as a dedicated ADC research entity within Gilead, with its Munich location serving as a central hub for the development of innovative ADC treatments. The union of these two strong entities is anticipated to not only advance Tubulis’ existing targets but also accelerate the overall innovation in oncology treatments, ultimately leading to improved patient outcomes worldwide.
This noteworthy transaction underscores the continued appetite in the market for innovative oncology platforms that can address pressing, unmet medical needs, paving the way for new advancements in treatment and potentially signaling a shift in how cancer therapies are developed and distributed globally.
As Gilead prepares for the close of this transformative deal, the biotech realm is keenly observing how this acquisition will influence future innovations in cancer treatment and the broader landscape of pharmaceutical development.
The transaction includes a cash payment of approximately $3.15 billion at closing, along with contingent milestone payments that could total another $1.85 billion. This strategic acquisition is expected to close in the second quarter of 2026 and will help Gilead enhance its clinical stage pipeline, particularly in the field of oncology, where there remains a critical need for innovative therapies.
EQT’s involvement with Tubulis dates back to March 2024, when the LSP 7 fund participated in a significant Series B2 financing round. Since then, EQT Life Sciences has played a vital role in the company's growth, providing strategic guidance and active board involvement, which helped position Tubulis as a formidable contender in the rapidly evolving ADC market.
Tubulis is known for its lead candidate, TUB-040, an ADC targeting NaPi2b that is currently undergoing Phase 1b/2 trials for both platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). In addition to TUB-040, Gilead will also acquire TUB-030, another promising ADC that targets the 5T4 antigen, showing encouraging results in initial clinical trials across various solid tumor types. This acquisition also includes Tubulis' early-stage pipeline and its advanced ADC platform, signaling Gilead’s intent to innovate within this space significantly.
Dominik Schumacher, CEO and co-founder of Tubulis, expressed optimism about joining forces with Gilead, citing the potential to leverage their expertise and resources for accelerated development of their promising ADC pipeline. This relationship is expected to deepen as both companies have already collaborated, showcasing the complementary strengths that can now be harnessed to meet critical patient needs.
Comments from Christoph Broja, a partner at EQT Life Sciences, reflected confidence in Tubulis' potential, emphasizing the unique innovation and scientific expertise present within the company. The decision to support Tubulis from its early days is viewed as a testament to EQT’s strategy of investing in companies that demonstrate remarkable ambition and technological prowess.
Post-acquisition, Tubulis will operate as a dedicated ADC research entity within Gilead, with its Munich location serving as a central hub for the development of innovative ADC treatments. The union of these two strong entities is anticipated to not only advance Tubulis’ existing targets but also accelerate the overall innovation in oncology treatments, ultimately leading to improved patient outcomes worldwide.
This noteworthy transaction underscores the continued appetite in the market for innovative oncology platforms that can address pressing, unmet medical needs, paving the way for new advancements in treatment and potentially signaling a shift in how cancer therapies are developed and distributed globally.
As Gilead prepares for the close of this transformative deal, the biotech realm is keenly observing how this acquisition will influence future innovations in cancer treatment and the broader landscape of pharmaceutical development.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.